mRNA 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global mRNA therapeutics market size is expected to reach USD 90.60 Billion in 2034 from USD 21.52 Billion in 2025, growing at a CAGR of 17.32% during 2026-2034.The global mRNA therapeutics market is experiencing rapid growth due to advancements in messenger RNA technology and its potential to treat a wide range of diseases. mRNA therapeutics work by delivering genetic instructions to cells, enabling them to produce specific proteins that can prevent or treat diseases. This innovative approach has gained significant attention in recent years due to its success in vaccine development.

Biotechnology companies and research institutions are exploring mRNA-based treatments for conditions such as cancer, genetic disorders, and infectious diseases. The flexibility of mRNA technology allows scientists to design therapies quickly and target specific disease mechanisms. Advances in delivery systems, such as lipid nanoparticles, are also improving the stability and effectiveness of mRNA therapeutics.

In the future, the market is expected to grow as clinical research continues to demonstrate the potential of mRNA-based treatments. Pharmaceutical companies are investing heavily in developing new therapeutic applications using this technology. As biotechnology innovation progresses, mRNA therapeutics are likely to become an important part of next-generation medical treatments.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

By Type

• Prophylactic
• Therapeutic

By End-use

• Hospitals & Clinics
• Research Organizations
• Others

COMPANIES PROFILED

• Moderna, BioNTech, Arcturus Therapeutics, CureVac, Translate Bio/Sanofi, Ethris, Arcturus, Capstan Therapeutics, ReNAgade Therapeutics, Strand Therapeutics, Replicate Bioscience, eTheRNA, Tiba Biotech, Acuitas Therapeutics, Beam Therapeutics, Intellia Therapeutics, Moderna Therapeutics, Cartesian Therapeutics, Sana Biotechnology, Orbimed-backed mRNA developers

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Respiratory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MRNA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MRNA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MRNA THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Type
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Type
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Type
  • 7.4.3 By End-use
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Type
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Type
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MRNA THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Moderna
  • 9.2.2 BioNTech
  • 9.2.3 Arcturus Therapeutics
  • 9.2.4 CureVac
  • 9.2.5 Translate Bio/Sanofi
  • 9.2.6 Ethris
  • 9.2.7 Arcturus
  • 9.2.8 Capstan Therapeutics
  • 9.2.9 ReNAgade Therapeutics
  • 9.2.10 Strand Therapeutics
  • 9.2.11 Replicate Bioscience
  • 9.2.12 ETheRNA
  • 9.2.13 Tiba Biotech
  • 9.2.14 Acuitas Therapeutics
  • 9.2.15 Beam Therapeutics
  • 9.2.16 Intellia Therapeutics
  • 9.2.17 Moderna Therapeutics
  • 9.2.18 Cartesian Therapeutics
  • 9.2.19 Sana Biotechnology
  • 9.2.20 Orbimed-backed MRNA Developers